HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmetics News In Brief: NY Slaps Limit On Cosmetic 1,4-Dioxane Content; J&J Talc Drama; IFF Merger

Executive Summary

Suspected trace carcinogen 1,4-dioxane must be limited to 2 parts per million in personal cleansing products sold in New York after 31 December 2022, and 1 ppm one year later, under recently enacted legislation. More cosmetics news in brief.

You may also be interested in...



DuPont’s Nutrition Business Spin-Off Through Subsidiaries Merger With IFF Moves Toward Closing

IFF announces preliminary results of more than 99% of votes approving issuing shares pursuant to an agreement that positions it as acquiring DuPont Nutrition & Biosciences under a “reverse Morris trust” transaction. The merger is between DuPont Nutrition & Biosciences and a subsidiary IFF established as a corporate entity to conduct the transaction.

Asbestos In Johnson's Baby Powder May Come From Test Labs, J&J Says

No asbestos found in 15 tests from same bottle FDA previously tested and reported finding asbestos. But a contractor's testing processes demonstrated potential for false findings of asbestos.

Industry Presses NY Governor Not To Sign 1,4-Dioxane Bill, Warns Of Far-Reaching Consequences

Market disruptions, “dramatically” higher prices, lost jobs and negative health consequences all are possible if legislation passed in New York in June to reduce 1,4-dioxane exposures is enacted in its current form, trade organizations say. Cleaning product industry advocates are leading the opposition, but personal-care manufacturers stand to be impacted as well.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel